At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 257 enrolled
Drug / intervention
Tirzepatide +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Phase 3, Double Blind Trial Comparing the Effect of the Addition of Tirzepatide Versus the Addition of Placebo to Titrated Basal Insulin on Glycemic Control in Chinese Participants With Type 2 Diabetes
In Brief
A Phase 3 clinical trial evaluating Tirzepatide and Placebo for Diabetes Type 2 and 4 related conditions. Completed, enrolled 257 participants across 25 sites.
Detailed Summary
The main purpose of this study is to compare the effect of the addition of tirzepatide or placebo to titrated basal insulin on glycemic control in Chinese participants with type 2 diabetes.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Type 2, Diabetes Mellitus, Glucose Metabolism Disorders, Metabolic Disease, Endocrine System Diseases
CountriesChina
Collaborators--
Timeline
Phase 3CompletedFinished
2023202420252026
First PostedJan 2023
Enrollment StartFeb 2023
Primary CompletionJul 2024
TodayJul 2026
First PostedJan 20, 2023
Enrollment StartFeb 5, 2023
Primary CompletionJul 1, 2024
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 3.4 years ago
Interventions
Tirzepatidedrug
Administered SC
Placebodrug
Administered SC